guidances for equine, porcine, and canine are part of the EAGR, and the aim of these three separate final guidances is to: (1) Be more specific for certain issues not discussed in the general guidance, (2) highlight differences with the EAGR on effectiveness data recommendations, and (3) give explanations for disparities between the EAGR and these documents.

These final level 1 guidance documents, developed under the VICH process, are consistent with FDA's good guidance practices regulation (21 CFR 10.115). These documents do not create or confer any rights for or on any person and will not operate to bind FDA or the public. An alternative method may be used as long as it satisfies the requirements of applicable statutes and regulations. (Information collected is covered under OMB control number 0910–0032.)

III. Comments

As with all of FDA's guidances, the public is encouraged to submit written or electronic comments with new data or other new information pertinent to these guidances. FDA will periodically review the comments in the docket and, where appropriate, will amend the guidances. The agency will notify the public of any such amendments through a notice in the Federal Register.

Interested persons may submit to the Dockets Management Branch (see ADDRESSES) written or electronic comments regarding these guidance documents at any time. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. A copy of the final guidance documents and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

IV. Electronic Access

Copies of the final guidance documents entitled "Effectiveness of Anthelmintics: Specific Recommendations for Equine" (VICH GL15), "Effectiveness of Anthelmintics: Specific Recommendations for Porcine" (VICH GL16), and "Effectiveness of Anthelmintics: Specific Recommendations for Canine" (VICH GL19) may be obtained on the Internet at http://www.fda.gov/cvm.

Dated: June 17, 2002.

Margaret M. Dotzel,

Associate Commissioner for Policy.
[FR Doc. 02–16292 Filed 6–26–02; 8:45 am]
BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Single Source Cooperative Agreement Award to the Brigham and Women's Hospital, Harvard University, Boston, MA

AGENCY: Center for Mental Health Services (CMHS), Substance Abuse and Mental Health Services Administration (SAMHSA), HHS.

ACTION: Notice of intent to award a single source cooperative agreement to Brigham and Women's Hospital, Harvard University, to support a program expansion and extension for the PRISMe multisite study Coordinating Center.

SUMMARY: The Center for Mental Health Services (CMHS), Substance Abuse and Mental Health Services Administration (SAMHSA), is publishing this notice to provide information to the public concerning a planned single source cooperative agreement award in the amount of \$500,000 in FY 2002, and \$500,000 in FY 2003 for a project period of two years to the Brigham and Women's Hospital, Harvard University. This is not a formal request for applications. Assistance will be provided only to Brigham and Women's Hospital based on the receipt of a satisfactory application that is approved by an independent review group.

Authority/Justification: The grant will be made under the authority of Section 520A of the Public Health Service Act, as amended. The award is intended to complete data analyses and write-up of the PRISMe multisite study findings, to complete the program manuals for the PRISMe study findings, and to produce an archive of the study database suitable for public use at the end of the project period. This award is being made on a single source basis because Brigham and Women's Hospital has coordinated the design and implementation of the PRISMe multisite study from which the additional data analyses, write-ups of study findings, program manuals, and archived database will be drawn. Making the award to another entity would require additional start-up time and costs, significant loss of critical

information, as well as duplication of previously completed work.

The Catalog of Federal Domestic Assistance (CFDA) number for this program is 93.243.

CONTACT: For more information about this program, contact: Betsy McDonel Herr, Ph.D., Government Project Officer, Community Support Branch, Division of Knowledge Development and Systems Change, Center for Mental Health Services (CMHS), SAMHSA, Room 11C–22 Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, (301) 594–2197, bmcdonel@samhsa.gov.

Dated: June 20, 2002.

Richard Kopanda,

 ${\it Executive Officer, SAMHSA.}$

[FR Doc. 02–16322 Filed 6–25–02; 1:58 pm]

BILLING CODE 4162-20-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Single Source Grant Award to the National Families in Action, Inc., Atlanta, GA

AGENCY: Center for Substance Abuse Prevention (CSAP), Substance Abuse and Mental Health Services Administration (SAMHSA), HHS.

ACTION: Notice of intent to award a single source grant to National Families in Action, Inc. to support updating, pilot testing and adaptation for different target audiences of the Basic Training I module for the National Parent Drug Prevention Corps.

SUMMARY: The Center for Substance Abuse Prevention (CSAP), Substance Abuse and Mental Health Services Administration (SAMHSA), is publishing this notice to provide information to the public concerning a planned single source grant award in the amount of \$100,000 in FY 2002 for a project period of one year to the National Families in Action (NFIA). This is not a formal request for applications. Assistance will be provided only to NFIA based on the receipt of a satisfactory application that is approved by an independent review group.

Authority/Justification: The grant will be made under the authority of section 516 of the Public Health Service Act, as amended. The award is intended to support updating, pilot testing, adaptation for different target audiences of the Basic Training I module that will be used in the National Parent Drug Prevention Corps activities that CSAP